SOLY - Soliton, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
12.29
+0.40 (+3.36%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.89
Open11.89
Bid0.00 x 900
Ask0.00 x 800
Day's Range11.11 - 12.49
52 Week Range4.12 - 15.00
Volume196,933
Avg. Volume208,800
Market Cap179.594M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.64
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Soliton to be Featured on Yahoo Finance's 'The First Trade' Show on May 13, 2019 to Discuss Cellulite Trial Results
    PR Newswire5 days ago

    Soliton to be Featured on Yahoo Finance's 'The First Trade' Show on May 13, 2019 to Discuss Cellulite Trial Results

    HOUSTON, April 18, 2019 /PRNewswire/ -- Soliton, Inc. (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that its Executive Chairman, Walter Klemp, will give a live interview on Yahoo Finance on Monday, May 13, 2019. As the Company has previously announced, data from its recently completed proof-of-concept clinical trial to study the safety and efficacy of a new version of its acoustic shockwave device for the treatment of moderate to severe cellulite will be presented to the scientific community at a national aesthetics conference, SCALE 2019 on May 11, 2019.  This interview with Yahoo Finance will cover this new data and what it means for Soliton going forward.

  • Soliton Announces Cellulite Trial Results to be Presented at National Aesthetics Conference on May 11, 2019
    PR Newswire8 days ago

    Soliton Announces Cellulite Trial Results to be Presented at National Aesthetics Conference on May 11, 2019

    HOUSTON, April 15, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that Dr. Elizabeth Tanzi of Capital Laser and Skin Care will present preliminary data from its completed cellulite clinical trial at the SCALE (Symposium for Cosmetic Advances and Laser Education) conference in Nashville, Tennessee to be held May 9-11, 2019.

  • Soliton Completes Cellulite Clinical Trials
    PR Newswire14 days ago

    Soliton Completes Cellulite Clinical Trials

    HOUSTON, April 9, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced it has completed the first evaluation timepoint for its proof of concept clinical trial for the treatment of cellulite. The study, conducted by Dr. Michael Kaminer at SkinCare Physicians in Boston, MA, in collaboration with Dr. Elizabeth Tanzi of Capital Laser and Skin Care, concluded evaluation of safety and efficacy for all patients through the initial 12-week time point.

  • Soliton Receives European Patent for Acoustic Shockwave Technology
    PR Newswire19 days ago

    Soliton Receives European Patent for Acoustic Shockwave Technology

    Rapid Acoustic Pulse device granted patent in Europe; a total of 11 issued patents and 42 pending patent applications in various countries HOUSTON , April 4, 2019 /PRNewswire/ -- Soliton, Inc., (NASDAQ: ...

  • Soliton Initiated Clinical Trials for Treatment of Cellulite in Humans
    PR Newswire22 days ago

    Soliton Initiated Clinical Trials for Treatment of Cellulite in Humans

    HOUSTON, April 1, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today summarized its efforts to conduct a proof of concept clinical trial for the treatment of cellulite based on Institutional Review Board ("IRB") approval of the study.  The study was initiated after positive results in animal studies indicated the potential for a higher-energy version of its acoustic shockwave technology to affect the factors contributing to the formation of cellulite.

  • Soliton Receives FDA Acceptance for 510(k) Application
    PR Newswire27 days ago

    Soliton Receives FDA Acceptance for 510(k) Application

    HOUSTON, March 27, 2019 /PRNewswire/ -- Soliton, Inc. (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that its 510(k) application for premarket clearance filed with the U.S. Food and Drug Administration ("FDA") for its first generation Rapid Acoustic Pulse ("RAP") tattoo removal device has cleared the agency's acceptance review. The application now moves to a substantive review. The device is indicated as an accessory to the 1064 nm Q-Switched (pulsed) laser for black ink tattoo removal on the arms, legs and torso in Fitzpatrick Skin Type I-III individuals.

  • Soliton Files 510(k) with FDA for its Rapid Acoustic Pulse Device
    PR Newswirelast month

    Soliton Files 510(k) with FDA for its Rapid Acoustic Pulse Device

    HOUSTON, March 21, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"),a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that it has filed for 510(k) premarket clearance with the U.S. Food and Drug Administration ("FDA") for its first generation Rapid Acoustic Pulse ("RAP") tattoo removal device.  The device is indicated as an accessory to the 1064 nm Q-Switched laser for black ink tattoo removal on the arms, legs and torso in Fitzpatrick Skin Type I-III individuals. Clinical trials have demonstrated that using the Company's RAP device, in conjunction with a Q-switched laser, allows for multiple passes of laser treatment in a single treatment session, resulting in accelerated fading in comparison to stand-alone laser treatment.  The current standard of care for tattoo removal is to use a Q-switched (pulsed) laser to ablate the tattoo ink particles into pieces small enough for the body's natural processes to remove them.

  • Soliton Completes Clinical Trials for Initial FDA Filing for Tattoo Indication
    PR Newswirelast month

    Soliton Completes Clinical Trials for Initial FDA Filing for Tattoo Indication

    HOUSTON , March 19, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed ...

  • Soliton to Present at Oppenheimer 29th Annual Healthcare Conference on March 20, 2019
    PR Newswirelast month

    Soliton to Present at Oppenheimer 29th Annual Healthcare Conference on March 20, 2019

    HOUSTON , March 18, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed ...

  • ACCESSWIRElast month

    Soliton Partners with Sanmina, a Global Medical Device Manufacturer

    HOUSTON, TX / ACCESSWIRE / March 14, 2019 / Soliton, Inc., (SOLY) (''Soliton'' or the ''Company''), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (''MD Anderson''), highlights the Company's important partnership with Sanmina Corporation to advance its acoustic shockwave technology into the commercialization phase in preparation for product launch.

  • ACCESSWIRElast month

    Soliton to Ring the Nasdaq Stock Market Closing Bell on March 19, 2019

    Ceremony available via livestream beginning at 3:45 p.m. ET HOUSTON, TX / ACCESSWIRE / March 12, 2019 / Soliton, Inc., (NASDAQ: SOLY) ("Soliton" or the "Company"), a medical device ...

  • ACCESSWIRE2 months ago

    Soliton's RAP Device Received Institutional Review Board Approval of Non-Significant Risk Designation

    HOUSTON, TX / ACCESSWIRE / March 8, 2019 / Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), discusses that their RAP device received institutional review board ("IRB") approval as a non-significant risk device. Subsequent to receiving this status, the Company conducted several human clinical trials to study the use of the RAP device to accelerate tattoo fading and initiated a proof-of-concept trial in humans for the reduction of cellulite.

  • ACCESSWIRE2 months ago

    Soliton Receives FDA Approval for Small Business Designation

    HOUSTON, TX / ACCESSWIRE / March 4, 2019 / Soliton, Inc., (SOLY) (''Soliton'' or the ''Company''), a medical device company with a novel and proprietary platform technology licensed from The University of Texas M.D. on behalf of the MD Anderson Cancer Center (''MD Anderson''), today announced that it has received notice from the U.S. Food and Drug Administration ("FDA") that the Company has qualified for the ''Small Business'' designation under the Medical Device User Fee Amendments (''MDUFA''). As a Small Business under the MDUFA, Soliton qualifies for a reduce or waived fee for medical device submissions made during the fiscal year 2019.

  • GlobeNewswire2 months ago

    Soliton Discusses Rapid Acoustic Pulse Technology for Treatment of Cellulite

    Soliton, Inc., (SOLY), (“Soliton” or the “Company”), a medical technology company that has developed a new breakthrough acoustic shockwave device, today announced that it believes that what they have discovered in preclinical testing with their Rapid Acoustic Pulse (“RAP”) technology may also give them the ability to reduce cellulite. The cells in the body that are responsible for synthesizing collagen and helping to maintain a well structured ECM are called “fibroblasts.” Soliton believes its RAP technology is capable of delivering a very compressed, high pressure shockwave at repetition rates of up to 100 per second, providing the necessary mechanical stress to induce fibroblast production of collagen without pain, or patient downtime.  In preclinical testing, the Company demonstrated that their RAP device is capable of consistently inducing the production of new collagen within the ECM of the dermis, therefore creating the potential for reducing the appearance of cellulite and skin laxity.

  • GlobeNewswire2 months ago

    Soliton Receives Additional Patent for Breakthrough Acoustic Shockwave Technology

    Dr. Chris Capelli, CEO of Soliton, said,  “The granting of this patent is an important milestone for Soliton. With the issuance of this patent in the People’s Republic of China (“PRC”) for our leading-edge Rapid Acoustic Pulse (“RAP”) technology and with our pending United States patents, we are well positioned to develop two of the major consumer markets in the world.

  • GlobeNewswire2 months ago

    Soliton, Inc. Completes IPO and Begins Trading on Nasdaq Under Ticker Symbol “SOLY”

    NEW YORK, HOUSTON and LOS ANGELES, Feb. 19, 2019 -- Soliton, Inc. (NASDAQ: SOLY) (“Soliton” or the “Company”), a pre-revenue stage medical device company with a novel and.